ARCHIVES

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

This article is from The Cancer Letter archive.

Vol. 05 No. 02 | January 12, 1979

Download PDF Visit The Full Archive

Related Articles

Revlimid Plus Steroid Effective In Clinical Trial

November 30, 2007

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

December 26, 2014

Alternative Medicine: Testing The Boundaries Of Science

May 15, 1998

Oxaliplatin Regimen May Beat Standard For Advanced Colorectal Cancer, NCI Says

May 3, 2002

In Brief: Best Guess On NCI Director: Brown First Choice, Benacerraf Second; FDa On Saccharin

April 22, 1977

NCI Cooperative Group Clinical Trials Approved

May 29, 2009